<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f124fad5-1e6a-4161-bc98-2b927e2df5d2"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use <content styleCode="bold">TRETINOIN</content> CAPSULES safely and effectively. See full prescribing information for <content styleCode="bold">TRETINOIN <content styleCode="bold">CAPSULES</content>
         </content>.</content>
      <br/>
      <br/>
      <content styleCode="bold">
         <content styleCode="bold">TRETINOIN </content>
         <content styleCode="bold">capsules,</content> for oral use </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1995</content>
   </title>
   <effectiveTime value="20250301"/>
   <setId root="9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119185057" root="1.3.6.1.4.1.519.1"/>
            <name>Endo USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="bcea6207-bc31-4da1-ab3a-5fb55f12a333"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241212"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="10370-268" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tretinoin</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Tretinoin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5688UTC01R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRETINOIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5688UTC01R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRETINOIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="REK4960K2U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYLATED HYDROXYANISOLE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N762921K75" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITROGEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="241ATL177A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SOYBEAN OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LECITHIN, SOYBEAN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2ZA36H0S2V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>YELLOW WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="10370-268-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20121024"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA201687" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20121024"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Opaque Body</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" displayName="brown" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Opaque Cap</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TR</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_a8fdd199-ff8e-4a7f-a8ec-d33ae6bf606a">
               <id root="07bb3f6a-163f-4606-a124-c6b8a0ccdda9"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: EMBRYO-FETAL TOXICITY and DIFFERENTIATION SYNDROME</content>
               </title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Tretinoin capsules can cause embryo-fetal loss and malformations when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Females of reproductive potential must have a negative pregnancy test before initiating tretinoin capsules. Advise females of reproductive potential to use two effective methods of contraception during treatment with tretinoin capsules and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with tretinoin capsules and for 1 week after the last dose <content styleCode="italics">[see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)]</content>.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Differentiation Syndrome, which can be life-threatening or fatal, occurred in about 26% of patients with APL who received tretinoin capsules. At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. Consider withholding tretinoin capsules for moderate and severe Differentiation Syndrome until resolution <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: EMBRYO-FETAL TOXICITY and DIFFERENTIATION SYNDROME</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Embryo-Fetal Toxicity: tretinoin capsules can cause embryo-fetal loss and malformations when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Females of reproductive potential must have a negative pregnancy test before initiating tretinoin capsules. Advise females of reproductive potential to use two effective methods of contraception during treatment with tretinoin <content styleCode="bold">capsules </content>and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with tretinoin capsules and for 1 week after the last dose. (5.1, 8.1, 8.3)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Differentiation Syndrome, which can be life-threatening or fatal, occurred in about 26% of patients with APL who received tretinoin capsules. At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. Consider withholding tretinoin capsules for moderate and severe Differentiation Syndrome until resolution. (5.2)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8d1779dc-2772-470c-a9be-7738fb052b55">
               <id root="75d64826-9f2b-4453-bd73-6fc9bed8eff7"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <effectiveTime value="20230301"/>
            </section>
         </component>
         <component>
            <section ID="LINK_1a6f4178-94d7-43cf-a243-875c3966f480">
               <id root="5a60ddcf-1be9-4dbf-b496-c668156d56fc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.</paragraph>
               </text>
               <effectiveTime value="20230301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tretinoin capsules are a retinoid indicated for induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL), characterized by presence of t(15;17) translocation or presence of PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_38e973d4-e1e3-4cf2-b682-251097990ee2">
               <id root="df3ce6aa-47d4-40db-9f27-a9e9a4de0b48"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20230301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>The recommended dosage of tretinoin capsules is 22.5 mg/m<sup>2</sup> orally twice daily until complete remission. (<linkHtml href="#LINK_fd052346-c2e2-433a-9ab9-e38b7cd60fec">2.2</linkHtml>)</item>
                           <item>Discontinue 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first. (<linkHtml href="#LINK_fd052346-c2e2-433a-9ab9-e38b7cd60fec">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_f6729ac4-bccd-4ea4-a8fd-7656cb64bd9b">
                     <id root="bab5fe04-9138-49f0-a734-84a51d28b7b0"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Important Safety Information</title>
                     <text>
                        <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating tretinoin capsules. Females of reproductive potential must have a negative pregnancy test before initiating tretinoin capsules <content styleCode="italics">[see Use in Specific Populations (8.3)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fd052346-c2e2-433a-9ab9-e38b7cd60fec">
                     <id root="33d7962d-5633-4bd8-9e9d-0a3424c0c231"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of tretinoin capsules is 22.5 mg/m<sup>2</sup> orally twice daily until complete remission is documented. Discontinue tretinoin capsules 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first.<br/>
                        </paragraph>
                        <paragraph>Discontinue tretinoin capsules if the t(15;17) translocation or PML/RARα fusion has not been identified <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>.</paragraph>
                        <paragraph>Take tretinoin capsules with a meal.</paragraph>
                        <paragraph>Swallow tretinoin capsules whole with water. Do not chew, dissolve, or open capsule.</paragraph>
                        <paragraph>Do not take a missed dose of tretinoin capsules unless it is more than 10 hours until the next scheduled dose.</paragraph>
                        <paragraph>If vomiting occurs after tretinoin capsules administration, do not take an additional dose, but continue with the next scheduled dose.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e1f71715-c1f6-44f3-b581-adb1426b4831">
               <id root="b01a72c8-db2b-469b-86eb-b4ff5b5fb5f0"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Capsules: 10 mg, two-tone (lengthwise) with reddish-brown opaque and yellow gelatin shell, imprinted with “TR” with black ink on the yellow side.</paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules: 10 mg (<linkHtml href="#LINK_e1f71715-c1f6-44f3-b581-adb1426b4831">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_69a67555-6e7a-4562-b4f1-537f19bf6e8f">
               <id root="2ab0ed62-a14a-4243-89df-51d9be39ef5a"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. Reactions have included rash, pruritus, face edema, and dyspnea <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_1879064b-cd92-46fd-a2e8-7c2992d81b23">6.1</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to tretinoin capsules, any of its components, or other retinoids </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_13b452c8-db3d-483b-8935-6fbb447baef9">
               <id root="356d47c2-8425-47b7-89f4-5805bc16bc74"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Patients Without t(15;17) Translocation or PML/RARα Fusion:</content> Tretinoin capsules may be initiated based on morphological diagnosis of APL. Confirm diagnosis by detection of the t(15;17) translocation or PML/RARα fusion. (<linkHtml href="#LINK_f28c0b61-288b-43c0-bf12-c6f30ec3d24d">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Leukocytosis:</content> Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated. (<linkHtml href="#LINK_4b6885a4-b03c-49b5-87dc-43d2013cf381">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Intracranial Hypertension:</content> Tretinoin capsules have been associated with benign intracranial hypertension, especially in pediatric patients. Consider interruption, dose reduction, or discontinuation of tretinoin capsules as appropriate. (<linkHtml href="#LINK_7a2d614a-48c2-4dff-9a34-2db17fc8e930">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Lipid Abnormalities:</content> Patients experienced hypercholesterolemia and/or hypertriglyceridemia, which may be reversible upon completion of treatment. Monitor fasting triglycerides and cholesterol at baseline and periodically during treatment. (<linkHtml href="#LINK_7a2d614a-48c2-4dff-9a34-2db17fc8e930">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity:</content> Monitor liver function test results at baseline and during treatment as clinically indicated. (<linkHtml href="#LINK_404fa852-a65c-44ae-ae55-3841eca88b03">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Thromboembolic Events:</content> Venous and arterial events have been reported; these events may occur during the first month of treatment with tretinoin capsules. (<linkHtml href="#LINK_140782c7-fb0a-41e7-a835-68eb4b9d75fb">5.8</linkHtml>, <linkHtml href="#LINK_7cdc0ecb-4083-42fd-9ee0-fd8fd8d6eb7b">7.4</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_f02d4567-69e2-45ca-afb9-545d8eb4ae98">
                     <id root="b99a4817-2f68-4c78-9f38-6c0b7a6002f4"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Tretinoin capsules can cause embryo-fetal loss and malformations when administered to a pregnant woman. Tretinoin capsules are a retinoid and there is an increased risk of major congenital malformations, spontaneous abortions and premature births following exposure to retinoids during pregnancy in humans. Tretinoin has teratogenic and embryotoxic effects in mice, rats, hamsters, rabbits and pigtail monkeys at doses less than the human dose on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use 2 effective methods of contraception during treatment with tretinoin capsules and for 1 month following the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with tretinoin capsules and for 1 week following the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_381c56ad-94fe-4803-af9c-f63778ea9802">8.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f1860927-7206-4419-a865-c8ccac674ef0">
                     <id root="39629d7e-d727-482a-b044-20e25acad101"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.2 Differentiation Syndrome</title>
                     <text>
                        <paragraph>Differentiation Syndrome, which may be life-threatening or fatal, occurred in about 26% of patients with APL who received tretinoin capsules <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. Symptoms include fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multi-organ failure. This syndrome has been accompanied by impaired myocardial contractility and episodic hypotension and it has been observed with or without concomitant leukocytosis. This syndrome generally occurs during the first month of treatment, as early as following the first dose. Endotracheal intubation and mechanical ventilation were required in some cases due to progressive hypoxemia and several patients have died with multi-organ failure.<br/>
                        </paragraph>
                        <paragraph>At the first signs or symptoms of this syndrome, immediately administer dexamethasone 10 mg intravenously every 12 hours until signs and symptoms have abated for at least 3 days and initiate hemodynamic monitoring until resolution of signs and symptoms. Consider withholding tretinoin capsules for moderate and severe differentiation syndrome until resolution <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_1879064b-cd92-46fd-a2e8-7c2992d81b23">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f28c0b61-288b-43c0-bf12-c6f30ec3d24d">
                     <id root="1be1d2bd-5487-4eb8-96b7-64274c69b044"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.3 Patients Without t(15;17) Translocation or PML/RARα Fusion</title>
                     <text>
                        <paragraph>Tretinoin capsules may be initiated based on the morphological diagnosis of acute promyelocytic leukemia (APL). Confirm the diagnosis of APL by detection of the t(15;17) translocation using cytogenetic studies or PML/RARα fusion using molecular diagnostic techniques. Tretinoin capsules are not recommended for use in patients without these genetic markers <content styleCode="italics">[see Indications and Usage (<linkHtml href="#www.splportal.comLINK_1a6f4178-94d7-43cf-a243-875c3966f480">1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4b6885a4-b03c-49b5-87dc-43d2013cf381">
                     <id root="4e562654-4804-456c-8fbc-5469da75cd67"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.4 Leukocytosis</title>
                     <text>
                        <paragraph>Rapidly evolving leukocytosis, which can be life-threatening, occurred in about 40% of patients with APL who received tretinoin capsules <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_1879064b-cd92-46fd-a2e8-7c2992d81b23">6.1</linkHtml>)]</content>. Patients who present with a baseline white blood cell count (WBC) &gt; 5 × 10<sup>9</sup>/L have an increased risk. Patients who receive chemotherapy with tretinoin capsules may be at a reduced risk. Rapidly evolving leukocytosis is associated with a higher risk of life-threatening complications.<br/>
                        </paragraph>
                        <paragraph>Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7a2d614a-48c2-4dff-9a34-2db17fc8e930">
                     <id root="b28eea3f-db6f-4511-81bb-ca2e39c9bac4"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.5 Intracranial Hypertension</title>
                     <text>
                        <paragraph>Retinoids, including tretinoin capsules, have been associated with intracranial hypertension, especially in pediatric patients. Early signs and symptoms include papilledema, headache, nausea, vomiting, and visual disturbances. Evaluate patients with these symptoms for intracranial hypertension, and, if present, institute appropriate care in concert with neurological assessment. Consider interruption, dose reduction, or discontinuation of tretinoin capsules as appropriate.</paragraph>
                        <paragraph>The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. Avoid concomitant use of tretinoin capsules with other products that can cause intracranial hypertension <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_5590f944-ba9e-43ef-b8c3-e4d08345f8e3">7.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e37e557c-1450-45d2-8438-5a088092b256">
                     <id root="a391936f-784e-49a8-8ac8-fe84ecc3eaf2"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.6 Lipid Abnormalities</title>
                     <text>
                        <paragraph>Hypercholesterolemia and/or hypertriglyceridemia has occurred in up to 60% of patients who received tretinoin capsules. These changes may be reversible upon completion of treatment. The clinical consequences of increased triglycerides and cholesterol are unknown, but venous thrombosis and myocardial infarction have been reported in patients who ordinarily are at low risk for such complications.</paragraph>
                        <paragraph>Monitor fasting triglycerides and cholesterol at baseline and periodically during treatment.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_404fa852-a65c-44ae-ae55-3841eca88b03">
                     <id root="7b5994f9-a66d-4002-9b62-cc1093225149"/>
                     <code code="50745-9" codeSystem="2.16.840.1.113883.6.1" displayName="VETERINARY INDICATIONS SECTION"/>
                     <title>5.7 Hepatotoxicity</title>
                     <text>
                        <paragraph>Elevated liver function test results occurred in 50% to 60% of patients during treatment with tretinoin capsules. Most of these abnormalities resolved without interruption of tretinoin capsules or after completion of treatment.<br/>
                        </paragraph>
                        <paragraph>Monitor liver function test at baseline and during treatment as clinically indicated. Consider withholding tretinoin capsules if liver function test results increase to greater than 5 times the upper limit of normal values until resolution.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_140782c7-fb0a-41e7-a835-68eb4b9d75fb">
                     <id root="ae01f13b-7a7e-4f07-8dad-5edb22857fbc"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.8 Thromboembolic Events</title>
                     <text>
                        <paragraph>Venous and arterial thromboembolic events, including cerebrovascular accident, myocardial infarction and renal infarct have been reported with tretinoin capsules <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_7963329b-5a2b-4ec2-b326-52e49e3966d1">6.2</linkHtml>)]. </content>These events may occur during the first month of treatment. Patients taking anti-fibrinolytic agents may have an increased risk.<br/>
                        </paragraph>
                        <paragraph>Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_7cdc0ecb-4083-42fd-9ee0-fd8fd8d6eb7b">7.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_675bbff7-5b49-4045-b686-aa2dff5fcb57">
               <id root="867248dd-7af2-4070-b93f-b19a9cac85b4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Differentiation Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_f1860927-7206-4419-a865-c8ccac674ef0">5.2</linkHtml>)]</content>
                     </item>
                     <item>Leukocytosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4b6885a4-b03c-49b5-87dc-43d2013cf381">5.4</linkHtml>)]</content>
                     </item>
                     <item>Intracranial hypertension <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>
                     </item>
                     <item>Lipid abnormalities <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_e37e557c-1450-45d2-8438-5a088092b256">5.6</linkHtml>)]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_404fa852-a65c-44ae-ae55-3841eca88b03">5.7</linkHtml>)]</content>
                     </item>
                     <item>Thromboembolic events <content styleCode="italics">[see Warnings and Precautions (5<linkHtml href="#www.splportal.comLINK_140782c7-fb0a-41e7-a835-68eb4b9d75fb">.8</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥30%) are headache, fever, skin/mucous membrane dryness, bone pain, malaise, shivering, upper respiratory tract disorders, dyspnea, hemorrhage, infections, nausea/vomiting, rash, peripheral edema, leukocytosis, pain, gastrointestinal hemorrhage, chest discomfort, abdominal pain (<linkHtml href="#LINK_1879064b-cd92-46fd-a2e8-7c2992d81b23">6.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-828-9393 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_1879064b-cd92-46fd-a2e8-7c2992d81b23">
                     <id root="11f0bccf-f4b6-4fae-827d-5b493a5764a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Acute Promyelocytic Leukemia</content>
                        </paragraph>
                        <paragraph>The safety of tretinoin capsules was evaluated in patients with APL who received tretinoin capsules at a dose of 22.5 mg/m<sup>2</sup> orally twice daily <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_8eb03509-2500-4e15-9e4f-c30bc27c809e">14</linkHtml>)]</content>.</paragraph>
                        <paragraph>The most common adverse reactions (≥30%) were headache, fever, skin/mucous membrane dryness, bone pain, malaise, shivering, upper respiratory tract disorders, dyspnea, hemorrhage, infections, nausea/vomiting, rash, peripheral edema, leukocytosis, pain, gastrointestinal hemorrhage, chest discomfort, abdominal pain.</paragraph>
                        <paragraph>Table 1 summarizes the adverse reactions for patients with APL.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Adverse Reactions (≥ 10%) Occurring in Patients with APL Who Received Tretinoin Capsules</content>
                        </paragraph>
                        <table width="387.667px">
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction</content> </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Tretinoin Capsules</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                       <content styleCode="bold">            All Grades</content>
                                    </paragraph>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Headache</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 86</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Dizziness</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 20</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Paresthesias</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Anxiety</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Insomnia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Depression</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Confusion</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">General disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Fever</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 83</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Skin/mucous membrane dryness</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 77</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Malaise</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 66</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Shivering</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 63</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Peripheral edema</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 52</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Pain</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 37</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Chest discomfort</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 32</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Edema</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 29</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Mucositis</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Weight increase</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Anorexia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Weight decrease</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Bone pain</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 77</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Myalgia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Upper respiratory tract disorders</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 63</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Dyspnea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 60</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Respiratory insufficiency</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Pleural effusion</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 20</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Rales</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Expiratory wheezing</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Pneumonia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Vascular disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Hemorrhage</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 60</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Gastrointestinal hemorrhage</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 34</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Flushing</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Hypotension</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Hypertension</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Phlebitis</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Infections and infestations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Infections</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 58</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Nausea/vomiting</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 57</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Abdominal pain</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 31</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Other gastrointestinal disorders</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Diarrhea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Constipation</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Dyspepsia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Abdominal distention</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Rash</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 54</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Pruritus</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 20</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Increased sweating</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 20</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Alopecia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Skin changes</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Blood and lymphatic system disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Leukocytosis</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 49</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Differentiation syndrome<sup>1</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Disseminated intravascular coagulation</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Ear and labyrinth disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Earache or feeling of fullness in the ears</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Cardiac disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Arrhythmias</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Eye disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Visual disturbances</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Ocular disorders</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Renal and urinary disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Renal insufficiency</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup>Differentiation syndrome can be associated with other commonly reported events<br/>
such as fever, leukocytosis, dyspnea, pneumonia, pleural effusion, pericardial effusion,<br/>
hypotension, edema, weight gain, and renal failure.</paragraph>
                        <paragraph>Adverse reactions that occurred in &lt;10% of patients who received tretinoin capsules include:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Hepatobiliary disorders: </content>Hepatosplenomegaly (9%), hepatitis (3%), unspecified liver disorder (3%).</item>
                           <item>
                              <content styleCode="italics">Musculoskeletal and connective tissue disorders: </content>Flank pain (9%), bone inflammation (3%).</item>
                           <item>
                              <content styleCode="italics">Nervous system disorders: </content>Agitation (9%), cerebral hemorrhage (9%), intracranial hypertension (9%), hallucination (6%), abnormal gait, agnosia, aphasia, asterixis, cerebellar edema, cerebellar disorders, convulsions, coma, CNS depression, dysarthria, encephalopathy, facial paralysis, hemiplegia, hyporeflexia, hypotaxia, no light reflex, neurologic reaction, spinal cord disorder, stroke, tremor, leg weakness, unconsciousness, dementia, forgetfulness, somnolence, and slow speech (3% each).</item>
                           <item>
                              <content styleCode="italics">Renal and urinary disorders: </content>Dysuria (9%), acute renal failure, micturition frequency, renal tubular necrosis, and enlarged prostate (3% each).</item>
                           <item>
                              <content styleCode="italics">Respiratory, thoracic and mediastinal disorders: </content>Lower respiratory tract disorders (9%), pulmonary infiltration (6%), bronchial asthma, pulmonary edema, larynx edema, and unspecified pulmonary disease (3% each).</item>
                           <item>
                              <content styleCode="italics">Infections and infestations: </content>Cellulitis (8%).</item>
                           <item>
                              <content styleCode="italics">Blood and lymphatic system disorders: </content>Lymph disorders (6%).</item>
                           <item>
                              <content styleCode="italics">Cardiovascular disorders: </content>Cardiac failure (6%), cardiac arrest, myocardial infarction, enlarged heart, heart murmur, myocarditis, pericarditis, and secondary cardiomyopathy (3% each).</item>
                           <item>
                              <content styleCode="italics">Ear and labyrinth disorders: </content>Hearing loss and other unspecified auricular disorders (6%), irreversible hearing loss (&lt;1%).</item>
                           <item>
                              <content styleCode="italics">General disorders: </content>Face edema (6%), pallor (6%), hypothermia (3%).</item>
                           <item>
                              <content styleCode="italics">Metabolism and nutrition disorders: </content>Fluid imbalance (6%), acidosis (3%).</item>
                           <item>
                              <content styleCode="italics">Eye disorders: </content>Changed visual acuity (6%), visual field defects (3%).</item>
                           <item>
                              <content styleCode="italics">Gastrointestinal disorders: </content>Ascites, ulcer (3% each).</item>
                           <item>
                              <content styleCode="italics">Vascular disorders: </content>Ischemia and pulmonary hypertension (3% each).</item>
                        </list>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7963329b-5a2b-4ec2-b326-52e49e3966d1">
                     <id root="6e0f5b29-8b87-47dc-9a4b-08192bd8bde2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2  Postmarketing Experience</title>
                     <text>
                        <paragraph>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Erythema nodosum, basophilia and hyperhistaminemia, Sweet’s Syndrome, organomegaly, hypercalcemia, pancreatitis, myositis, thrombosis (both venous and arterial), thrombocytosis, genital ulceration and vasculitis, predominantly involving the skin.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_223f5dda-8854-4b08-8818-b2186a22090c">
               <id root="2a215761-d74a-403c-8b40-d921d1596bf7"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Strong CYP3A Inhibitors and Inducers:</content> Avoid coadministration with strong CYP3A inhibitors and inducers. (<linkHtml href="#LINK_53fa7271-4f15-42c5-baa9-e5da68720d3b">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Concomitant Use of Products Known to Cause Intracranial Hypertension</content>: Avoid concomitant use with other products that can cause intracranial hypertension. (<linkHtml href="#LINK_5590f944-ba9e-43ef-b8c3-e4d08345f8e3">7.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Vitamin A</content>: Avoid concomitant use with vitamin A. (<linkHtml href="#LINK_a31758db-44e6-4e27-a496-5c40368198b2">7.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Anti-fibrinolytic Agents</content>: Avoid concomitant use with anti-fibrinolytic agents. (<linkHtml href="#LINK_7cdc0ecb-4083-42fd-9ee0-fd8fd8d6eb7b">7.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_53fa7271-4f15-42c5-baa9-e5da68720d3b">
                     <id root="9835d0f5-0855-4a10-a843-6cbc60fc1f82"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.1  Effects of Other Drugs on Tretinoin Capsules</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Strong <content styleCode="underline">or moderate</content> CYP3A Inhibitors</content>
                        </paragraph>
                        <paragraph>Avoid concomitant use of tretinoin capsules with strong CYP3A inhibitors if possible and monitor more frequently if concomitant use is unavoidable. Monitor patients taking moderate CYP3A inhibitors concomitantly with tretinoin capsules more frequently for adverse reactions.</paragraph>
                        <paragraph>Tretinoin is a CYP3A substrate. Concomitant use with a strong CYP3A4 inhibitor increases tretinoin plasma concentrations, which may increase the risk of adverse reactions <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#LINK_969fd8b8-d313-46fb-9ba5-364abcc95b56">12.3</linkHtml>)]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Strong CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>Concomitant use of tretinoin capsules with strong CYP3A4 inducers may decrease tretinoin plasma concentrations, which may reduce its efficacy. Avoid concomitant use with strong CYP3A inducers if possible.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5590f944-ba9e-43ef-b8c3-e4d08345f8e3">
                     <id root="93724814-20f5-4432-a751-f310ddfef303"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.2 Concomitant Use of Products Known to Cause Intracranial Hypertension</title>
                     <text>
                        <paragraph>Intracranial hypertension has been reported in patients who received tretinoin capsules and concomitant use of other products that can cause intracranial hypertension, such as tetracyclines, may increase the risk. Avoid concomitant use of tretinoin capsules with other products agents that can cause intracranial hypertension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7a2d614a-48c2-4dff-9a34-2db17fc8e930">5.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a31758db-44e6-4e27-a496-5c40368198b2">
                     <id root="a06e9b8b-ff92-402f-a584-2aba5767bb50"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.3 Vitamin A</title>
                     <text>
                        <paragraph>The concomitant use of vitamin A with tretinoin capsules may lead to vitamin A related adverse reactions. Avoid concomitant use of tretinoin capsules with vitamin A.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7cdc0ecb-4083-42fd-9ee0-fd8fd8d6eb7b">
                     <id root="50fde1f9-3a6f-4ccf-8f6b-97bf3bae327e"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.4 Anti-fibrinolytic Agents</title>
                     <text>
                        <paragraph>Fatal thrombotic complications have been reported in patients who have received tretinoin capsules and concomitant use of anti-fibrinolytic agents may increase the risk. Avoid concomitant use of tretinoin capsules with anti-fibrinolytic agents <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_140782c7-fb0a-41e7-a835-68eb4b9d75fb">5.8</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b71d5682-2a94-4ce2-83c7-a044461b6223">
               <id root="454bac6f-c772-4baf-a474-b33b2a436249"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#LINK_9fb94c6e-6139-479a-93cd-1e0bc5032850">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e475f237-3e80-443e-8922-4a4c39273af8">
                     <id root="5817feeb-b46c-41b4-a2df-116e5a780151"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on findings in animals and its mechanism of action <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_109e07f7-fdc8-43e8-88c7-0624788fd053">12.1</linkHtml>)], </content>tretinoin capsules can cause embryo-fetal loss and malformations when administered to a pregnant woman. Tretinoin capsules are a retinoid and there is an increased risk of major congenital malformations, spontaneous abortions and premature births following exposure to retinoids during pregnancy in humans. Tretinoin was teratogenic and embryotoxic in mice, rats, hamsters, rabbits and pigtail monkeys at doses less than the human dose on a mg/m<sup>2</sup> basis <content styleCode="italics">(see Data)</content>. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the</paragraph>
                        <paragraph>U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph> Tretinoin capsules are a retinoid and increased spontaneous abortions and major fetal abnormalities related to the use of retinoids have been documented in humans. Reported malformations include abnormalities of the central nervous system, musculoskeletal system, external ear, eye, thymus and great vessels; and facial dysmorphia, cleft palate, and parathyroid hormone deficiency. Some of these abnormalities were fatal. </paragraph>
                        <paragraph>IQ scores less than 85, with or without obvious CNS abnormalities, have been reported in pediatrics exposed to retinoids <content styleCode="italics">in utero</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Tretinoin causes fetal resorptions and a decrease in live fetuses in all animals studied. Gross external, soft tissue and skeletal alterations occurred at doses higher than 0.7 mg/kg/day in mice, 2 mg/kg/day in rats, 7 mg/kg/day in hamsters, and at a dose of 10 mg/kg/day, the only dose tested, in pigtail monkeys (about 1/20, 1/4, and 1/2 and 4 times the human dose, respectively, on a mg/m<sup>2</sup> basis).</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9fb94c6e-6139-479a-93cd-1e0bc5032850">
                     <id root="1cd7d75b-7bbc-4ce0-ab8b-526dce72a35d"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>There are no data on the presence of tretinoin in human milk, the effects on the breastfeed child or the effects on milk production. Because of the potential for serious adverse reactions from tretinoin capsules in breastfed infants, advise women not to breastfed during treatment with tretinoin capsules and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_381c56ad-94fe-4803-af9c-f63778ea9802">
                     <id root="e93079b1-857b-43d6-ae45-6e679c0bdc7c"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Use in Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Tretinoin capsules can cause embryo-fetal loss and malformations when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>
                           </content>)<content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating tretinoin capsules. Females of reproductive potential must have a negative pregnancy test within 1 week prior to initiating tretinoin capsules with a sensitivity of at least 50 mIU/mL.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to abstain continuously from sexual intercourse or to use two effective methods of contraception. Counsel patients to use two effective methods of contraception during treatment with tretinoin capsules and for 1 month after the last dose. Two methods of effective contraception is indicated even where there has been a history of infertility, unless due to hysterectomy. Refer females of reproductive potential to a qualified provider of contraceptive methods, if needed.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during and after treatment with tretinoin capsules and for 1 week after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on testicular toxicities observed in dogs, tretinoin capsules may impair male fertility <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_af61a3a7-a3d9-4d7b-8e82-e12325cb9e22">13.1</linkHtml>)]</content>. The reversibility of effect on fertility is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1ca0239b-22b7-4bd5-8bcd-c5c871643a94">
                     <id root="8d76d998-d074-4e65-84a4-0362fa5c1051"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of tretinoin capsules have been established in pediatric patients 1 year of age and older and the information on this use is discussed throughout the labeling. The maximum tolerated dose is lower in pediatric patients compared to adults. Some pediatric patients experience severe headache and intracranial hypertension, which required management with an analgesic and a lumbar puncture. Dose reduction may be considered for pediatric patients experiencing serious and/or intolerable adverse reactions.</paragraph>
                        <paragraph>Safety and effectiveness in pediatric patients less than 1 year of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f60b4c4a-5239-4bb7-9430-823e555c3a4c">
                     <id root="142f8a25-6402-4347-8d13-6aa31bcecf4a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Across clinical studies of tretinoin capsules, 21% were 60 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9e47edab-ebe5-404f-8cb7-f532580e560e">
               <id root="274fd7ea-b4a2-4e31-ba0a-f152a5d50aa4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In case of overdose with tretinoin capsules, reversible signs of hypervitaminosis A (headache, nausea, vomiting, mucocutaneous symptoms) can appear. Overdosage with other retinoids has been associated with transient headache, facial flushing, cheilosis, abdominal pain, dizziness and ataxia. These symptoms have quickly resolved without apparent residual effects.</paragraph>
                  <paragraph>There is no specific treatment in the case of an overdose; however, it is important that the patient be treated in a special hematological unit.</paragraph>
               </text>
               <effectiveTime value="20230301"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9fa5bd52-b8bd-4b60-879b-ab91a1fe80d0">
               <id root="db3f0289-2c71-45a2-a8a3-cab89384f998"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Tretinoin is a retinoid. The chemical name is all-trans retinoic acid. The molecular formula is C<sub>20</sub>H<sub>28</sub>O<sub>2 </sub>and the molecular weight is 300.44 g/mol. The structural formula is:</paragraph>
                  <paragraph>                                                                           <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>It is a yellow to light orange, crystalline powder with melting point at about 182°C (with decomposition). Tretinoin is practically insoluble in water, sparingly soluble in methylene chloride, and slightly soluble in ethanol (96%).</paragraph>
                  <paragraph>Tretinoin capsules are available as capsules containing 10 mg tretinoin for oral use. Each capsule also contains butylated hydroxyanisole, edetate disodium, soybean oil, hydrogenated vegetable oils, medium chain triglycerides, soya lecithin, and yellow beeswax. The gelatin capsule shell contains gelatin, glycerin, yellow iron oxide, red iron oxide and titanium dioxide. Capsules are printed with edible black ink, which consist of propylene glycol, iron oxide black, polyvinyl acetate phthalate and polyethylene glycol 400. </paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>The molecular formula for Tretinoin.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="tretinoin-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4ca1b0cf-ebdd-4d52-94b6-847c8842a368">
               <id root="daeae7a7-bfee-4678-8bfb-81ceb80cbe59"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250301"/>
               <component>
                  <section ID="LINK_109e07f7-fdc8-43e8-88c7-0624788fd053">
                     <id root="41fd9a4a-9366-4b24-a68c-2cdea08bfef0"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Tretinoin induces cytodifferentiation and decreased proliferation of APL cells in culture and <content styleCode="italics">in vivo</content>. In APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f635b5eb-8e89-407c-8125-7eea66df92f7">
                     <id root="2e34b4e6-63be-4d55-8150-6c8be41c1acb"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of tretinoin capsules have not been characterized.</paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_969fd8b8-d313-46fb-9ba5-364abcc95b56">
                     <id root="226fde0c-c202-4343-aebe-b815016fc5ae"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following the administration of tretinoin capsules 22.5 mg/m<sup>2</sup> orally twice daily, the mean ± SD peak tretinoin concentrations after the first dose was 394 ± 89 and after 1 week of continuous treatment was 138 ± 139 ng/mL, while area under the curve (AUC) after the first dose was 537 ± 191 ng·h/mL and after 1 week of continuous treatment was 249 ± 185 ng·h/mL.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Time to reach peak concentration was between 1 and 2 hours. The absolute bioavailability of tretinoin capsules was approximately 50%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>The effect of food on the absorption of tretinoin capsules has not been characterized. Food increases the absorption of retinoids, as a class.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The apparent volume of distribution of tretinoin has not been determined.</paragraph>
                        <paragraph>Protein binding is greater than 95%, predominately to albumin. Plasma protein binding remains constant over the concentration range of 10 to 500 ng/mL.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The terminal elimination half-life of tretinoin following initial dosing is 0.5 to 2 hours in patients with APL.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Tretinoin induced its own metabolism with plasma concentrations after 1 week of continuous therapy decreased to one-third of their day 1 values. Tretinoin is metabolized by cytochrome P450 enzymes, CYP3A4, 2C8, and 2E and undergoes glucuronidation by UGT2B7. Metabolites include 9-<content styleCode="italics">cis </content>retinoic acid, 13-<content styleCode="italics">cis </content>retinoic acid, 4-oxo <content styleCode="italics">trans </content>retinoic acid, 4-oxo <content styleCode="italics">cis </content>retinoic acid, and 4-oxo <content styleCode="italics">trans </content>retinoic acid glucuronide. The metabolites 4-oxo retinoic acid and 4-oxo <content styleCode="italics">trans </content>retinoic acid glucuronide have one-third of the pharmacological activity of the parent compound.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following administration of radiolabeled tretinoin 2.75 mg and 50 mg (0.53 to 9.6 times the approved recommended dosage based on 1.7 m<sup>2</sup>), approximately 63% of radioactivity was recovered in the urine within 72 hours and 31% appeared in the feces within 6 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>The effect of age, sex, race, renal impairment, and hepatic impairment on the pharmacokinetics of tretinoin is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies </content>
                           <content styleCode="italics">and Post Marketing Experience</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Strong CYP3A inhibitors:</content>
                           </content> Tretinoin AUC increased by 72% following concomitant use with ketoconazole (strong CYP3A inhibitor). Increased tretinoin toxicity has also been reported post-marketing with strong CYP3A inhibitors including certain antimycotics.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Moderate CYP3A Inhibitors:</content>
                           </content> Increased tretinoin toxicity following concomitant use of tretinoin capsules with certain antimycotics that are moderate CYP3A4 inhibitors has been reported post-marketing.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Tretinoin on Transporters: </content>Tretinoin does not inhibit P-gp and BCRP <content styleCode="italics">in vitro</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_af61a3a7-a3d9-4d7b-8e82-e12325cb9e22">
               <id root="4ded2a3a-9dd0-46b7-bccb-a36491a69757"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230301"/>
               <component>
                  <section ID="LINK_a8412dda-6543-4fa6-a3c6-8f5cdbc1b59b">
                     <id root="ea1436c8-681d-4e8b-8252-31c2857081df"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No 2-year carcinogenicity studies in rodents have been conducted with tretinoin. In a carcinogenicity study, female B5D2F1 mice pretreated with a carcinogen diethylnitrosamine (DEN, intraperitoneal 50 mg/kg and 100 mg/kg) received dietary supplement of all-trans-retinoic acid (tretinoin) for 12 months. Tretinoin at a dose of 30 mg/kg/day in the diet (about 2 times the human dose on a mg/m<sup>2</sup> basis) was shown to increase the rate of DEN-induced mouse hepatocellular carcinomas. Tretinoin in combination with 50 mg/kg of DEN also increased the incidence of hemangiomas and hemangiosarcomas.</paragraph>
                        <paragraph>Tretinoin was negative when tested in the Ames and Chinese hamster V79 cell HGPRT assays for mutagenicity. A 2-fold increase in the sister chromatid exchange (SCE) has been demonstrated in human diploid fibroblasts, but other chromosome aberration assays, including an <content styleCode="italics">in vitro</content> assay in human peripheral lymphocytes and an <content styleCode="italics">in vivo</content> mouse micronucleus assay, did not show a clastogenic or aneuploidogenic effect.</paragraph>
                        <paragraph> Adverse effects on fertility and reproductive performance were not observed in studies conducted in rats at doses up to 5 mg/kg/day (about 2/3 the human dose on a mg/m<sup>2</sup> basis). In a 6-week toxicology study in dogs, testicular degeneration, with increased numbers of immature spermatozoa, were observed at 10 mg/kg/day (about 4 times the equivalent human dose in mg/m<sup>2</sup>).<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8eb03509-2500-4e15-9e4f-c30bc27c809e">
               <id root="fc6eb853-8131-4a88-b763-6962601b2f82"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of tretinoin capsules has been evaluated in 114 previously treated patients and in 67 previously untreated (“de novo”) patients with APL in one open-label, uncontrolled single investigator clinical study (Memorial Sloan-Kettering Cancer Center [MSKCC]) and in two cohorts of compassionate cases treated by multiple investigators under the auspices of the National Cancer Institute (NCI). Patients received tretinoin capsules 22.5 mg/m<sup>2</sup> orally twice daily for up to 90 days following the first dose or 30 days following achievement of complete remission. Efficacy results are shown Table 2.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2. Efficacy Results in a Controlled Clinical Trial (MSKCC) and Compassionate Use</content>
                  </paragraph>
                  <table width="714.667px">
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>
              </td>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">MSK</content>
                                 <content styleCode="bold">CC</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">NCI Cohort 1</content>
                           </td>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">NCI Cohort 2</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">Relapsed</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">N = 20</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">De Novo</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">n = 15</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">Relapsed*</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">N = 48</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">De Novo</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">n = 14</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">Relapsed</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">n = 46</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> <content styleCode="bold">De Novo<sup>†</sup>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">n = 38</content>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Complete<br/>
            Remission</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 16 (80%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11 (73%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24 (50%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5 (36%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24 (52%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26 (68%)</td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Median<br/>
            Survival</paragraph>
                              <paragraph>(months)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10.8</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NR</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5.8</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0.5</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8.8</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NR</td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Median<br/>
            Follow-up</paragraph>
                              <paragraph>(months)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 9.9</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 42.9</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5.6</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1.2</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8.0</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 13.1</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>NR = Not Reached </paragraph>
                  <paragraph>NA = Not Available</paragraph>
                  <paragraph>
                     <sup>*</sup>Including 9 chemorefractory patients</paragraph>
                  <paragraph>
                     <sup>†</sup>Including 8 patients who received chemotherapy but failed to enter remission</paragraph>
                  <paragraph>The median time to complete remission was between 40 and 50 days (range: 2 to 120 days). Most patients received cytotoxic chemotherapy during the remission phase.</paragraph>
                  <paragraph>Ten of 15 pediatric cases achieved complete remission (8 of 10 males and 2 of 5 females).</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250301"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3ceb622d-982e-49a2-a328-cd25052315e9">
               <id root="a7684bb1-f5e8-4364-bf9b-5a1123d400e3"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Tretinoin capsules are supplied as 10 mg capsules, two-tone (lengthwise) with reddish-brown opaque and yellow gelatin shell, imprinted with “TR” with black ink on the yellow side. Supplied in high-density polyethylene, opaque bottles of 100 capsules available in:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>100 count bottles with child-resistant closure                         NDC 10370-268-01</item>
                  </list>
                  <paragraph>Store at 20ºC to 25ºC (68ºF to 77ºF); [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Keep bottle tightly closed. Protect from light.</paragraph>
               </text>
               <effectiveTime value="20230301"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d38ead44-9d40-4373-8a80-2b9d50b07074">
               <id root="63152993-52c2-4f59-8e70-47174235c625"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise female patients of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_f02d4567-69e2-45ca-afb9-545d8eb4ae98">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_381c56ad-94fe-4803-af9c-f63778ea9802">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>Advise females of reproductive potential to use 2 methods of effective contraception during treatment with tretinoin capsules and for 1 month after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_381c56ad-94fe-4803-af9c-f63778ea9802">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with tretinoin capsules and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_381c56ad-94fe-4803-af9c-f63778ea9802">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Differentiation Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that tretinoin capsules can cause differentiation syndrome. Ask patients to immediately report any symptoms suggestive of differentiation syndrome, such as fever, cough or difficulty breathing, decreased urinary output, low blood pressure, rapid weight gain, or swelling of their arms or legs, to their healthcare provider for further evaluation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_f1860927-7206-4419-a865-c8ccac674ef0">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Patients Without t(15;17) Translocation or PML/RARα Fusion</content>
                  </paragraph>
                  <paragraph>Advise patients that tretinoin capsules are not recommended for use in patients without t(15;17) translocation or PML/RARα fusion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_f28c0b61-288b-43c0-bf12-c6f30ec3d24d">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Leukocytosis</content>
                  </paragraph>
                  <paragraph>Inform patients that rapidly evolving leukocytosis, which can be life-threatening, can occur during treatment with tretinoin capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4b6885a4-b03c-49b5-87dc-43d2013cf381">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Intracranial Hypertension</content>
                  </paragraph>
                  <paragraph>Advise patients that tretinoin capsules can cause intracranial hypertension, especially in pediatric patients. Ask patients to immediately report any symptoms suggestive of intracranial hypertension, such as headache, nausea, vomiting, and visual disturbances <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7a2d614a-48c2-4dff-9a34-2db17fc8e930">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lipid Abnormalities</content>
                  </paragraph>
                  <paragraph>Inform patients that hypercholesterolemia and/or hypertriglyceridemia can occur during treatment with tretinoin capsules. Advise patients on the need for monitoring fasting triglycerides and cholesterol <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_e37e557c-1450-45d2-8438-5a088092b256">5.6</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients that tretinoin capsules can cause elevated liver function tests. Advise patients on the need for monitoring of liver function tests <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_404fa852-a65c-44ae-ae55-3841eca88b03">5.7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Thromboembolic Events</content>
                  </paragraph>
                  <paragraph> Inform patients that venous and arterial thromboembolic events, including cerebrovascular accident, myocardial infarction and renal infarct can occur during treatment with tretinoin capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_140782c7-fb0a-41e7-a835-68eb4b9d75fb">5.8</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with tretinoin capsules and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9fb94c6e-6139-479a-93cd-1e0bc5032850">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients to swallow tretinoin capsules whole with water. Advise patients not to chew, dissolve, or open capsules. Advise patients not to take a missed dose of tretinoin capsules unless it is more than 10 hours until the next scheduled dose. Advise patients that if vomiting occurs after tretinoin capsules administration, that they should not take an additional dose, but continue with the next scheduled dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_fd052346-c2e2-433a-9ab9-e38b7cd60fec">2.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Effects on Ability to Drive and Use Machines</content>
                  </paragraph>
                  <paragraph>Advise patients that the ability to drive or operate machinery might be impaired when treated with tretinoin capsules, particularly if patients are experiencing dizziness or severe headache.</paragraph>
                  <paragraph>Manufactured for:<br/>
Endo USA<br/>
Malvern, PA 19355</paragraph>
                  <paragraph>Made in France</paragraph>
                  <paragraph>© 2024 Endo, Inc. or one of its affiliates.</paragraph>
                  <paragraph>Revised: 03/2025</paragraph>
               </text>
               <effectiveTime value="20250301"/>
            </section>
         </component>
         <component>
            <section ID="LINK_57979418-ae16-401f-9445-1ed0b8e564db">
               <id root="e12bc36f-6285-43f6-bcc3-74741eddf2b0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>NDC 10370-<content styleCode="bold">268</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Tretinoin Capsules 10 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CAUSES BIRTH DEFECTS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DO NOT GET PREGNANT</content>
                  </paragraph>
                  <paragraph>Contains the active ingredient found in Vesanoid*</paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: PLEASE DISPENSE WITH ATTACHED PATIENT INFORMATION LEAFLET.</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">PATIENT READ INFORMATION LEAFLET CAREFULLY</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each capsule contains:</content>
                     <br/>
Tretinoin................10 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content> See package outsert for full prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.</content>
                  </paragraph>
                  <paragraph>Dispense in tight, light-resistant container. [see USP]</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20ºC to 25ºC (68ºF to 77ºF). [see USP Controlled Room Temperature].</content>
                     <br/>
                     <content styleCode="bold">Protect from light.</content>
                  </paragraph>
                  <paragraph>R08/2024</paragraph>
                  <paragraph>Manufactured for:<br/>
Endo USA<br/>
Malvern, PA 19355</paragraph>
                  <paragraph>Made in France</paragraph>
                  <paragraph>*Vesanoid is a registered trademark of Roche<br/>
Laboratories Inc. Endo, Inc. is not affiliated with Roche Laboratories Inc.</paragraph>
               </text>
               <effectiveTime value="20230301"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>This is an image of tretinoin capsules 10 mg, 100 capsule bottle label.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="tretinoin-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>